Obesity in the spotlight (part VI)

What's old is new again (or "how the obesity drug market mirrors the cancer market from 10 years ago")

For those who’ve been around for a little while (and remember Boutique Biotech’s previous obesity post from last year), there may be some similarities noted between what the cancer drug market looked like about 10 years ago and what we now see the obesity drug market shaping up to be.

Specifically, GLP-1 drugs are quickly emerging as the cornerstone tre…